加拿大人20年间骨密度与骨折变化:加拿大骨质疏松多中心研究与加拿大老龄化纵向研究的比较
比较相隔20年招募的两个加拿大队列(CaMos 1995-1997年,N=6479;CLSA 2012-2015年,N=19534)50-85岁人群的股骨颈骨密度和主要骨质疏松性骨折患病率,调整协变量后发现新近招募的CLSA队列骨密度更高、骨折患病率更低,双膦酸盐使用增加但男性仍很低。
要点
- 调整协变量后,CaMos女性股骨颈骨密度较CLSA低0.017 g/cm2(95%CI -0.021至-0.014),男性低0.006 g/cm2(95%CI -0.011至0.000)。
- CaMos女性主要骨质疏松性骨折患病风险较CLSA高(OR 1.99,95%CI 1.71-2.30),男性也高(OR 2.33,95%CI 1.82-3.00)。
- 有骨折的女性中,CaMos补充剂使用(32.0% vs 48.3%,p<0.001)和双膦酸盐使用(5.8% vs 17.3%,p<0.001)均低于CLSA;男性骨折后双膦酸盐使用两队列均低于10%。
核心结论
- 调整多个协变量后,新近招募的CLSA队列较CaMos队列骨密度更高、骨折患病率更低。
- 近期队列双膦酸盐使用增加,但男性仍非常低。
研究设计与样本
- 研究纳入加拿大骨质疏松多中心研究(CaMos,N=6479,1995-1997年)和加拿大老龄化纵向研究(CLSA,N=19534,2012-2015年)中50-85岁男性和女性。
- 采用回归模型比较两队列股骨颈骨密度和骨折风险,并调整重要协变量;在主要骨质疏松性骨折患者中比较抗骨质疏松药物使用。
主要发现
- CaMos平均(SD)年龄65.4岁(8.6)高于CLSA的63.8岁(9.1);CaMos平均体重指数更低、吸烟率更高(p<0.001)。
- 调整线性回归模型显示,CaMos女性股骨颈骨密度较CLSA低0.017 g/cm2(95%CI -0.021至-0.014),男性低0.006 g/cm2(95%CI -0.011至0.000)。
- 调整比值比(95%CI)显示,CaMos女性主要骨质疏松性骨折患病风险较CLSA高(1.99 [1.71; 2.30]),男性也高(2.33 [1.82; 3.00])。
- 有主要骨质疏松性骨折的女性中,更年期激素治疗使用两队列相似(43.3% vs 37.9%,p=0.076),但CaMos补充剂使用(32.0% vs 48.3%,p<0.001)和双膦酸盐使用(5.8% vs 17.3%,p<0.001)低于CLSA。
- 有主要骨质疏松性骨折的男性中,接受双膦酸盐治疗的比例在两队列均低于10%。
关键数值与推荐
- 调整后股骨颈骨密度差值:CaMos女性较CLSA低0.017 g/cm2(95%CI -0.021至-0.014),男性低0.006 g/cm2(95%CI -0.011至0.000)。
- 主要骨质疏松性骨折患病比值比:CaMos女性OR 1.99(95%CI 1.71-2.30),男性OR 2.33(95%CI 1.82-3.00),均以CLSA为参照。
- 女性骨折后药物使用比较:更年期激素治疗43.3% vs 37.9%(p=0.076),补充剂32.0% vs 48.3%(p<0.001),双膦酸盐5.8% vs 17.3%(p<0.001),均为CaMos vs CLSA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: International variations in osteoporosis and fracture rates have been reported, with temporal trends differing between populations. We observed higher BMD and lower fracture prevalence in a recently recruited cohort compared to that of a cohort recruited 20 years ago, even after adjusting for multiple covariates. PURPOSE: We explored sex-specific differences in femoral neck bone mineral density (FN-BMD) and in prevalent major osteoporotic fractures (MOF) using two Canadian cohorts recruited 20 years apart. METHODS: We included men and women aged 50-85 years from the Canadian Multicentre Osteoporosis Study (CaMos, N = 6,479; 1995-1997) and the Canadian Longitudinal Study on Aging (CLSA, N = 19,534; 2012-2015). We created regression models to compare FN-BMD and fracture risk between cohorts, adjusting for important covariates. Among participants with prevalent MOF, we compared anti-osteoporosis medication use. RESULTS: Mean (SD) age in CaMos (65.4 years [8.6]) was higher than in CLSA (63.8 years [9.1]). CaMos participants had lower mean body mass index and higher prevalence of smoking (p < 0.001). Adjusted linear regression models (estimates [95%CI]) demonstrated lower FN-BMD in CaMos women (- 0.017 g/cm2 [- 0.021; - 0.014]) and men (- 0.006 g/cm2 [- 0.011; 0.000]), while adjusted odds ratios (95%CI) for prevalent MOF were higher in CaMos women (1.99 [1.71; 2.30]) and men (2.33 [1.82; 3.00]) compared to CLSA. In women with prevalent MOF, menopausal hormone therapy use was similar in both cohorts (43.3% vs 37.9%, p = 0.076), but supplements (32.0% vs 48.3%, p < 0.001) and bisphosphonate use (5.8% vs 17.3%, p < 0.001) were lower in CaMos. The proportion of men with MOF who received bisphosphonates was below 10% in both cohorts. CONCLUSION: Higher BMD and lower fracture prevalence were noted in the more recently recruited CLSA cohort compared to CaMos, even after adjusting for multiple covariates. We noted an increase in bisphosphonate use in the recent cohort, but it remained very low in men.
引用
- Hassanabadi N, Berger C, Papaioannou A, et al. Variation in bone mineral density and fractures over 20 years among Canadians: a comparison of the Canadian Multicenter Osteoporosis Study and the Canadian Longitudinal Study on Aging. Osteoporos Int. 2022. PMID: 36449036. doi:10.1007/s00198-022-06623-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。